Trials / Completed
CompletedNCT03961529
Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis
A Multicenter, Open-label, Uncontrolled, Long-term Trialto Demonstrate the Safety and Efficacy of 1% OPA-15406 Ointment in Adult Patients With Atopic Dermatitis and of 0.3% and 1% OPA-15406 Ointments in Pediatric Patients With Atopic Dermatitis (Phase 3 Trial)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 366 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and 1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.3% OPA-15406 ointment | Twice daily |
| DRUG | 1% OPA-15406 ointment | Twice daily |
Timeline
- Start date
- 2019-05-14
- Primary completion
- 2020-11-11
- Completion
- 2020-11-11
- First posted
- 2019-05-23
- Last updated
- 2021-11-19
- Results posted
- 2021-11-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03961529. Inclusion in this directory is not an endorsement.